Document is current
Any future updates will be listed below
-
Authors
Huang, Can
Santofimia-Castaño, Patricia
Liu, Xi
Xia, Yi
Peng, Ling
Gotorbe, Célia
Neira, Jose Luis
Tang, Daolin http://orcid.org/0000-0002-1903-6180
Pouyssegur, Jacques
Iovanna, Juan http://orcid.org/0000-0003-1822-2237
-
Funding
Funding for this research was provided by:
Institut National Du Cancer
Canceropôle PACA
- License Information
-
More Information
Article History
Received: 20 July 2021
Revised: 20 August 2021
Accepted: 7 September 2021
First Online: 1 October 2021
Competing interests
: JI is co-founder of PanCa Therapeutics. PS-C, YX, LP, JLN, and JI are inventors of the Patent “NUPR1 INHIBITION FOR TREATING CANCER”, Application number WO-2019229236-A1. The remaining authors declare no competing interests. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.
